AMANDA GRIMES to Infant
This is a "connection" page, showing publications AMANDA GRIMES has written about Infant.
Connection Strength
0.463
-
Predictors of response to emergent therapies in paediatric immune thrombocytopenia. Br J Haematol. 2025 Nov; 207(5):2091-2098.
Score: 0.080
-
Genetic variants in canonical Wnt signaling pathway associated with pediatric immune thrombocytopenia. Blood Adv. 2024 11 12; 8(21):5529-5538.
Score: 0.076
-
Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation. Eur J Haematol. 2021 Jun; 106(6):783-787.
Score: 0.059
-
A Case of a Very Young Child With T Lymphoblastic Lymphoma With Eosinophilia and PDGFRB Translocation: A Rare Form of Myeloid/Lymphoid Neoplasm Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB or FGFR1. Clin Lymphoma Myeloma Leuk. 2020 12; 20(12):e990-e993.
Score: 0.057
-
Pediatric ITP: is it different from adult ITP? Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):405-411.
Score: 0.050
-
Megaloblastic Anemia Progressing to Severe Thrombotic Microangiopathy in Patients with Disordered Vitamin B12 Metabolism: Case Reports and Literature Review. J Pediatr. 2018 11; 202:315-319.e2.
Score: 0.049
-
Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial. JAMA. 2025 11 25; 334(20):1816-1826.
Score: 0.020
-
Real-World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia. Pediatr Blood Cancer. 2026 Jan; 73(1):e32143.
Score: 0.020
-
Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences. Blood. 2020 07 30; 136(5):640-643.
Score: 0.014
-
Fatigue in children and adolescents with immune thrombocytopenia. Br J Haematol. 2020 10; 191(1):98-106.
Score: 0.014
-
The cost of a "benign" condition: Healthcare utilization and infectious outcomes in young children with primary autoimmune neutropenia. Pediatr Blood Cancer. 2020 04; 67(4):e28146.
Score: 0.014
-
Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders. Pediatr Blood Cancer. 2018 Jan; 65(1).
Score: 0.011